Evaluating in Vivo PARP-1 Expression With 18F-FluorThanatrace Positron Emission Tomography (PET/CT) in Prostate Cancer

NCT03334500 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

ACTIVE_NOT_RECRUITING

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Prostate Cancer

Interventions

DEVICE: [18F]FluorThanatrace
DRUG: Poly(ADP Ribose) Polymerase 1

Sponsor

Abramson Cancer Center at Penn Medicine